Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Investigating Cooking and Culinary Expressions: An Excursion Through Flavors - 2Pentagon advances Golden Dome missile defense with new Space Force contracts
- 3Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 4Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- 5New electric car registrations rise sharply in Germany in March
- the 6 Shrewd Beds for seniors: A Complete Survey
- France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown
- Rescuers attempt to dig free whale stranded on Germany's Baltic coast
- Shrewd Home Gadgets to Save Energy
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- How Skoda Lost Its Biggest Market In Just Seven Years
- Well known Travel Booking Locales: What's Your Pick?
- Guinea-Bissau's coup called a 'sham' by West African political figures
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
